Harvard Pilgrim signs outcomes-based contracts with AstraZeneca for Brilinta and Bydureon

Harvard Pilgrim Health Care

30 May 2017 - Effectiveness in actual patients will be measured.

Harvard Pilgrim Health Care has signed two innovative, outcomes-based contracts with AstraZeneca for medicines to treat acute coronary disease and type 2 diabetes. These are the latest two in a series of agreements the health plan has executed with pharmaceutical companies that measure the effectiveness of medicines in actual patients.

The first is a three-year contract for Brilinta, a medication used to lower a patient's chances of having another heart attack or dying from one.

Harvard Pilgrim will be monitoring specific criteria in patients following discharge from a hospitalisation for acute coronary syndrome. The outcome will focus on measuring the reduction in hospitalisations for repeat acute coronary events for patients on Brilinta as compared to patients on another oral anti-platelet therapy.

Read Harvard Pilgrim press release

Michael Wonder

Posted by:

Michael Wonder